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Wereportacaseoftorsadedepointesafterintravenousamiodaroneandconcurrenthypokalemia.Despitetreatmentcessationand
correction of electrolyte abnormalities, excessive QTc prolongation was noted, which persisted for 14 days. This prolonged course
for QTc normalization may be attributed to the high rate of amiodarone loading and concurrent electrolyte disturbances coupled
with possible underlying individual variability in pharmacokinetics.
1.Introduction
Amiodarone is a safe antiarrhythmic agent, associated with
low proarrhythmia rates. However, a few cases of torsade
de pointes have been reported after intravenous amio-
darone[1–4].Bydeﬁnition,drug-inducedQTcprolongation
normalizes after drug discontinuation, but, in the case of
amiodarone, this time the interval is not well deﬁned.
We describe a case of excessive QTc prolongation after
intravenous amiodarone that persisted for 14 days after
treatment cessation. To our knowledge, such long-lasting
QTc prolongation after intravenous amiodarone has not
been described previously.
2.CaseDescription
A 57-year-old male, with unremarkable cardiovascular his-
tory, had a self-terminated episode of atrial ﬁbrillation
(Figure 1) one day prior to surgery for hiatus hernia. After
the episode, the electrocardiogram was normal, with a QTc
interval of 420ms. Postoperatively, atrial ﬁbrillation with
rapid ventricular response was recorded, which was treated
with intravenous amiodarone at an infusion rate of approx-
imately 2mg/min, following initial rapid administration of
150mg over 10 minutes. Sinus rhythm was restored after 1
hour, but drug administration was continued for 12 hours,
with a total amiodarone dosage of 1.65g (Figure 1).
QTc prolongation (at 623ms) associated with hypo-
kalemia (K+ :2.54meq/L) was noted and the patient was
placed under continuous telemetry recording. Approxi-
mately 48 hours after amiodarone administration, torsade
de pointes was recorded (Figure 2) and prompt deﬁbrilla-
tion restored sinus rhythm. An acute coronary syndrome
was ruled out and echocardiography was normal. Despite
intravenous potassium and magnesium administration, two
further episodes of torsade de pointes occurred, requiring
the addition of isoproterenol infusion for 24 hours. At this
time point, normal serum electrolyte values were recorded
(Na+ :138meq/L,K+ :4.79meq/L,Mg ++ :1.7meq/L)andthe
patient subsequently remained arrhythmia-free on telemetry
recording. However, prolonged hospitalization was required,
because QTc prolongation persisted until the 14th hospital
day (Figure 3).
Blood biochemistry and thyroid function tests were
normal and serum potassium was within normal limits
duringtheremaininghospitalizationperiod.AlthoughGitel-
man syndrome [5] was initially considered, this diagnosis
was subsequently excluded, due to the absence of further
electrolyte disturbances on repeated measurements during
the follow-up period. The patient was discharged home on2 Case Reports in Medicine
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Figure 1: Baseline QTc. QTc interval was normal prior to amiodarone administration (day 0); after 1.65g intravenous amiodarone, QTc
increased progressively.
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Figure 2: Torsade de pointes after amiodarone administration.
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Figure 3: Time course of QTc prolongation. QTc prolongation persisted for 14 days after cessation of intravenous amiodarone. Note the
(marginally) low serum K+ on the 4th hospital day.
the15thhospitalday,atwhichpointaQTcintervalof470ms
was recorded (Figure 4).
Andersen-Tawil Syndrome was excluded because there
were no dysmorphic features and no history of muscle
cramping or paralysis. The possibility of latent inherited
long QT syndrome, unmasked by amiodarone, was consid-
ered according to previous experience [6], but the patient
declined genetic testing. During a 10-month follow-up
period, he remained asymptomatic and serial electrocardio-
grams were normal, as were electrocardiograms from ﬁrst-
degree relatives.
3. Discussion
Although side eﬀects after intravenous amiodarone are rare
and this therapy is generally considered safe, torsade de
pointes has been previously described [1–4]. The causes of
amiodarone-induced torsade de pointes are multifactorial,
with electrolyte disturbances and concomitant medication
with other QT-prolonging agents being the most common
risk factors. In our patient, hypokalemia was considered
a signiﬁcant contributing factor to torsade de pointes.
However, with the exception of low serum potassium (ofCase Reports in Medicine 3
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Figure 4: 12-lead ECG at discharge. Prior to discharge, the QTc interval was 470ms.
borderline signiﬁcance) documented on the 4th hospital day,
long QT was noted despite normal potassium levels, thereby
excluding hypokalemia alone as a cause of persistent QT
prolongation.
The cause of hypokalemia in our patient is not entirely
clear, but it should be most likely attributed to the combined
eﬀectofthe(presumed)postoperativecatecholaminerelease,
along with nonrenal potassium loss, associated with the
(short-term) use of nasogastric suction; in addition, isopro-
terenol infusion after the episodes of torsade de pointes may
have been a contributory factor. This view is reinforced by
the exclusion of other possible causes of hypokalemia, such
as total body potassium depletion, including diuretic use
and chronic alcoholism, as well as (primary and secondary)
hyperaldosteronism.
Of note, the repolarization changes observed in precor-
dial leads during the postoperative period may raise the
possibility of Brugada syndrome, but this diagnosis was
subsequently excluded, based on the absence of ST segment
elevation in serial electrocardiograms during the hospital-
ization and follow-up period. It is likely that repolarization
abnormalities (inverted T waves) in the precordial leads
m a yh a v eb e e nc a u s e db yp o s t o p e r a t i v ec a t e c h o l a m i n es u r g e ,
coupled with isoproterenol infusion; thus, acquired long QT
syndrome due to stress-cardiomyopathy was considered, but
the echocardiogram was not suggestive.
Given the very long half-life of amiodarone, electrocar-
diographicﬁndingsafteroraladministrationmaynotresolve
beforeseveraldaysorweeksafterdiscontinuationofthedrug
[7]. However, despite some paucity of data, there is evidence
from animal [8]a n dh u m a n[ 9] studies, in agreement with
earlier reports [10], suggesting that pharmacokinetics after
intravenous amiodarone display wide variation, but are
generally more rapid than after oral administration. In
concertwiththisdata,thetimecourseforQTcnormalization
after intravenous amiodarone in previous reports [2–4]
r a n g e df r o m1t o5d a y s .
T o r s a d ed ep o i n t e sh a sb e e np r e v i o u s l yr e p o r t e d[ 4]a f t e r
650mg of intravenous amiodarone, followed by oral sotalol
and ciproﬂoxacine; QTc normalized 3 days after discontin-
uation of these agents [4]. In another case, QTc normalized
one day after 570mg intravenous amiodarone [2]. However,
in a further patient, QTc prolongation persisted for 5
days after 450mg intravenous amiodarone, possibly due to
concurrent methadone treatment [3]. In contrast with these
ﬁndings, themostinteresting observation inour casewasthe
markedly prolonged time-course of QTc lengthening, which
normalized 15 days after 1.65g amiodarone administration.
Although the total amiodarone loading dose of 1.65g
in our case is higher than in previous reports [2–4], acute
administration at dosages exceeding 2.0g is common in
clinical practice [11, 12]. However, despite the wide vari-
ability [12], the rate of amiodarone loading of 2mg/min,
chosen in the present paper, appears to be higher than
most previously published regimens [13], rendering this a
potential explanation for the observed side eﬀect.
4. Conclusion
The time interval for QTc normalization after intravenous
amiodarone varies, likely, due to the unique pharmacokinet-
ics of this agent. Our patient developed acquired long QT
syndrome in the setting of rapid amiodarone loading and
hypokalemia, which resulted in torsade de pointes. In similar
clinicalscenarios,normalizationoftheQTcintervalmaytake
longer than previously reported and prolonged monitoring
may be needed.4 Case Reports in Medicine
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